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acute GVHD (p¼0.71). Only BKV subtype III had a statistically
signiﬁcant correlation with HC (OR: 10.8, 95%CI: 1.64-70.93,
p¼0.013).
Conclusion: BKV is ubiquitous among humans, infecting
children asymptomatically and then persisting in renal
tissue. Subtype Ic is most prevalent (>90%), followed by
subtype IV, while subtype III are rarely found in Japan. Our
data suggested the importance of BKV subtype III in the
development of BKV-HC. Further studies focused on the viral
genomic variation in the pathogenesis of BKV-HC are
warranted.
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Background: Allogeneic hematopoietic cell transplantation
(alloHCT) is the only option for cure for many patients with
hematological malignancies such as leukemia and MDS;
however many patients, especially the older population,
cannot tolerate full-intensity ablative conditioning regimens.
Fludarabine and melphalan has been efﬁcacious as a reduced
intensity conditioning regimen for alloHCT for multiple
malignancies, but the relapse rate for this regimen remains
high. We have replaced ﬂudarabine with clofarabine,
a rationally designed second-generation purine nucleoside
analog. Clofarabine has increased immunosuppressive and
anti-leukemic activity compared to ﬂudarabine in vitro, and
we have found in a phase I study that the clofarabine/
melphalan conditioning regimen for alloHCT in patients with
acute leukemia or MDS is safe and tolerable. We hypothe-
sized that analysis of outcomes for patients treated using thisregimen would demonstrate favorable relapse rates while
maintaining a low-toxicity proﬁle.
Patients & Methods: Twenty patients with high-risk
leukemia or MDS, with a median age of 63 years, underwent
alloHCT from November 2007 until June of 2012. Patients
were treated at one of three dose levels of a clofarabine (day
-9 to day -5) and melphalan (on day -4) conditioning
regimen: 3 patients received 30 mg/m2 clofarabine and 100
mg/m2 melphalan (dose level 1), 12 patients received 40 mg/
m2 clofarabine and 100mg/m2melphalan (dose level 2), and
5 patients received 40 mg/m2 clofarabine and 140 mg/ m2
melphalan (dose level 3). The ﬁrst 16 patients were included
in a phase 1 prospective study and 4 additional patients were
treated at dose level 3 off protocol. Graft-versus-host-disease
(GVHD) prophylaxis began on day -3with the combination of
tacrolimus and sirolimus.
Results: The median follow-up for surviving patients was
28.7months (1.1 - 52.9). Overall survival at 1 year and 2 years
was 77% and 70 % respectively. Event-free survival at 1 and 2
years was the same, at 70.7% (95% CI: 52.1 - 83.2). Fifty
percent of patients experienced acute GVHD (grades I and II
only), and 69% of evaluable patients experienced chronic
GVHD. The majority of toxicities were related to the gastro-
intestinal system including elevated liver enzymes with one
patient experiencing grade 4 hepatic toxicity. Other adverse
events included renal insufﬁciency (5 patients), CNS toxicity
(2 patients), and cardiac toxicity (1 patient).
Conclusion: The combination of clofarabine and high dose
melphalan is a well tolerated conditioning regimen that
provides a durable remission and event-free survival of 70.7%
in patients with high-risk disease. We are planning to initiate
a phase 2 trial to examine the anti-leukemic activity of dose
level 3 for this clofarabine/melphalan reduced-intensity
alloHCT regimen in patients with high-risk acute myeloge-
nous leukemia.
Overall Survival and Event Free Survival Patients treated with Clo/Mel at 30/
100 (n¼3), 40/100 (n¼12), 40/140 (n¼5) Transplant Date Range: 11/28/2007-
06/28/2012.
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